LEXINGTON, Mass., June 1, 2017 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of
immune checkpoint antibodies and cancer vaccines, today announced
that the Company will present at the following conferences to be
held in New York City,
USA:
- The 2017 Jefferies Healthcare Conference:
-
- Jennifer Buell, Ph.D., Vice
President of Research and External Affairs will present on
Tuesday, June 6th at
10:30 a.m. EST.
- The 2017 JMP Securities Life Sciences Conference:
-
- Jean-Marie Cuillerot, M.D., Chief Medical Officer will
participate in a panel session titled "Immuno-oncology: Checkpoints
as Targets" on Wednesday, June
21st at 9 a.m.
EST.
Webcast Information
The live and archived webcast of the
Jefferies presentation will be accessible from the
Company's website at www.agenusbio.com/webcast. Please log in
approximately 5-10 minutes before the event to ensure a timely
connection. A replay will be available on the Company's website
approximately two hours after the call and will remain available
for 90 days.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing a number of combination approaches that leverage a broad
repertoire of antibody therapeutics and proprietary cancer vaccine
platforms. The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is based in Lexington, MA. For more
information, please visit www.agenusbio.com; information that may
be important to investors will be routinely posted on our
website.
Forward-Looking Statement
This press release contains forward-looking statements that
are made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company's
planned participation in two upcoming conferences. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
Contact:
Agenus Inc.
Michelle Linn,
781-674-4541
michelle.linn@agenusbio.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-to-participate-at-two-upcoming-conferences-in-new-york-city-jefferies-healthcare-and-jmp-securities-life-sciences-300466932.html
SOURCE Agenus Inc.